← boardnext 2028-09
MOLN
Molecular Partners AGdistress 3/10 · well-funded / low risk$3.97-3%today-23% from 52w high
Oncology 1
Lead: Large Cell Neuroendocrine Carcinoma
Revenue
pre-revenue
Liquidity
$79M
Runway
1.5 yrs
Shares 1y
0%
Price & events
-1.0% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.4%
1D
+1.5%
1W
+0.5%
1M
-8.5%
3M
-1.0%
6M
+6.4%
1Y
-38.4%
2Y
-79.5%
5Y
-79.8%
All
Overview
- Market Cap
- $160.29M
- Volume
- 300
- 52 Week Range
- $3.47 – $5.13
- Total Shares
- 40.37M
- Float Shares
- 19.92M
- Short %
- 0.01%
- % Held by Insiders
- 0.00%
- % Held by Institutions
- 9.58%
- RVOL
- 0.04x
- Beta
- 0.67
Pipeline stages · 2 programs
[212Pb]Pb-MP0712
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 2 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-09 Estimated 50% readout ~2028-10-16 | Phase 1/2 | [212Pb]Pb-MP0712 | Large Cell Neuroendocrine Carcinoma, Large Cell Pulmonary Neuroendocrine Carcinoma of the Lung (LCNEC), Extrapulmonary Neuroendocrine Carcinoma (EP-NEC), Small Cell Lung Cancer (SCLC), Gastroenteropancreatic NEC (GEP NEC), NEC of the Bladder, Other DLL3 Expressing epNEC | — | recruiting |
| 2026-05-29 | Phase 1/2 | MP0533 (multispecific DARPin CD3 Engager Targeting CD33, CD123 and CD70) monotherapy, Part | Leukemia, Myeloid, Acute, Newly Diagnosed | 249 | active not recruiting |
Catalyst news & presentations · 0
- No catalyst news yet.
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $11 (+177% upside) · 5 analysts
- 2026-04-22HC Wainwright & Co.Buy
- 2026-03-16HC Wainwright & Co.Buy
- 2026-01-27HC Wainwright & Co.Buy
- 2025-12-08JP MorganNeutral
- 2025-09-03JP MorganNeutral
- 2025-03-11LifeSci CapitalOutperform
Competitors — Large Cell Neuroendocrine Carcinoma
- NVSEFNOVARTIS AG$292.0B · D3
Recent news
- 2026-07-20Molecular Partners Starts Phase 2 TACTIC Trial of MP0317 in Front-Line Cholangiocarcinoma - TipRanks
- 2026-07-20Molecular Partners (NASDAQ: MOLN) begins MP0317 Phase 2 TACTIC study - Stock Titan
- 2026-07-19MOLN Stock Price and Chart — NASDAQ:MOLN - TradingView
- 2026-07-16Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma - The Manila Times
- 2026-07-15Molecular Partners Develops Two-Target Cancer Radiopharmaceuticals - Stock Titan
- 2026-07-15Molecular Partners Highlights Bispecific Radio-DARPin Approach to Target Tumor Heterogeneity in Cancer - Quiver Quantitative
- 2026-07-08Molecular Partners (MOLN) Gains 2.25% as Buyers Test Resistance Near $4.29 - AD Line Divergence - dars.gov.et
- 2026-07-07Molecular Partners (NASDAQ: MOLN) details progress in Radio-DARPin cancer pipeline - Stock Titan
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.